D.E. Shaw & Co’s GeneDx Holdings Warrant WGSWW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.74K Hold
467,197
﹤0.01% 4446
2025
Q4
$22.1K Hold
467,197
﹤0.01% 4479
2025
Q3
$51.2K Hold
467,197
﹤0.01% 4397
2025
Q2
$30.8K Hold
467,197
﹤0.01% 4203
2025
Q1
$98.1K Hold
467,197
﹤0.01% 4020
2024
Q4
$74.8K Hold
467,197
﹤0.01% 4184
2024
Q3
$34.5K Hold
467,197
﹤0.01% 4313
2024
Q2
$13.9K Hold
467,197
﹤0.01% 4295
2024
Q1
$25.7K Hold
467,197
﹤0.01% 4102
2023
Q4
$5.56K Hold
467,197
﹤0.01% 4171
2023
Q3
$14K Hold
467,197
﹤0.01% 4032
2023
Q2
$3.32K Hold
467,197
﹤0.01% 4134
2023
Q1
$8.64K Hold
467,197
﹤0.01% 4253
2022
Q4
$8.88K Sell
467,197
-31,136
-6% -$3.21K ﹤0.01% 4621
2022
Q3
$108K Hold
498,333
﹤0.01% 4587
2022
Q2
$162K Hold
498,333
﹤0.01% 4613
2022
Q1
$344K Hold
498,333
﹤0.01% 4582
2021
Q4
$488K Hold
498,333
﹤0.01% 4416
2021
Q3
$1.06M Hold
498,333
﹤0.01% 3562
2021
Q2
$2.29M Hold
498,333
﹤0.01% 2805
2021
Q1
$2.52M Buy
+498,333
New +$2.77M ﹤0.01% 2391

Other funds holding WGSWW

D.E. Shaw & Co's WGSWW Position: Q1 2026 in Review

D.E. Shaw & Co held its GeneDx Holdings Warrant (WGSWW) position steady in Q1 2026 at 467,197 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4446.

D.E. Shaw & Co first reported a position in WGSWW in Q1 2021 and has held it in 21 quarters since. The position peaked at $2.52M in Q1 2021. 13 funds tracked by Wall St. Rank hold WGSWW as of Q1 2026.

  • D.E. Shaw & Co held 467,197 shares of GeneDx Holdings Warrant worth $3.74K as of Q1 2026.
  • D.E. Shaw & Co left its GeneDx Holdings Warrant share count unchanged in Q1 2026.
  • GeneDx Holdings Warrant made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4446 holding.
  • D.E. Shaw & Co first reported a position in GeneDx Holdings Warrant in Q1 2021 and has held it in 21 quarters since.
  • D.E. Shaw & Co's GeneDx Holdings Warrant position peaked at $2.52M in Q1 2021.
  • 13 funds tracked by Wall St. Rank held GeneDx Holdings Warrant as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.